Combined Oxidative Phosphorylation Deficiency 38 (COXPD38) Cell Models for Research

Combined Oxidative Phosphorylation Deficiency 38 (COXPD38) is an ultra-rare autosomal recessive mitochondrial disorder caused by mutations in the VARS2 gene, encoding mitochondrial valyl-tRNA synthetase. The exact prevalence is unknown, but fewer than 50 cases have been reported worldwide. Onset is typically in infancy or early childhood, with symptoms including hypotonia, developmental delay, seizures, cardiomyopathy, and lactic acidosis. Prognosis is poor, with many patients succumbing in early childhood. According to the National Institutes of Health (NIH), the disorder is part of a broader group of mitochondrial diseases affecting oxidative phosphorylation. The rarity and severity underscore the need for research models to understand pathophysiology and test potential therapies.

COXPD38 serves as an ideal model for studying mitochondrial tRNA synthetase dysfunction and its impact on oxidative phosphorylation. The disease is monogenic, allowing for precise genetic manipulation. Public datasets, such as those in ClinVar and the Human Gene Mutation Database (HGMD), provide mutation information. Open questions include the tissue-specific effects of VARS2 mutations and potential therapeutic targets. Gene-edited cell models enable mechanistic studies and drug screening.

The primary pathway affected is mitochondrial translation. VARS2 is essential for charging mitochondrial tRNA-Val with valine, a step required for protein synthesis within mitochondria. Mutations lead to defective mitochondrial translation, impairing the assembly of respiratory chain complexes I, III, IV, and V. This results in reduced ATP production and increased reactive oxygen species (ROS). The following steps outline the pathogenesis:

1. VARS2 gene mutation leads to reduced or absent enzymatic activity.

2. Mitochondrial tRNA-Val is not properly aminoacylated.

3. Mitochondrial protein synthesis is impaired.

4. Respiratory chain complexes are deficient, particularly complexes I and IV.

5. Oxidative phosphorylation is uncoupled, leading to ATP depletion and ROS overproduction.

6. Cellular damage and apoptosis occur, especially in high-energy-demand tissues (brain, muscle, heart).

Data compiled from ClinVar and literature reports.

Mitochondrial dysfunction in COXPD38 affects several signaling pathways:

• • AMPK pathway: Activated in response to low ATP/AMP ratio, promoting catabolism and mitochondrial biogenesis.
• • mTORC1 pathway: Inhibited due to energy stress, reducing protein synthesis and cell growth.
• • Apoptotic pathways: Increased ROS and cytochrome c release trigger intrinsic apoptosis.
• • Calcium signaling: Mitochondrial calcium uptake is impaired, affecting neuronal signaling.
• • Inflammatory pathways: ROS activate NF-κB and NLRP3 inflammasome, leading to chronic inflammation.

Key nodes include AMPK, mTOR, BAX/BAK, and NF-κB.

Organoids, particularly brain organoids, are valuable for studying neuronal involvement. They can be generated from patient iPSCs and recapitulate disease features.

• • Patient-derived xenografts (PDX): Not applicable for mitochondrial diseases as they are not oncological.
• • Genetically engineered mouse models (GEMM): Vars2 knockout mice have been generated, showing embryonic lethality in homozygotes, while heterozygotes show mitochondrial dysfunction.
• • Induced models: CRISPR-Cas9 can introduce patient-specific mutations into mouse embryos to create point-mutation models.
• • Zebrafish models: Morpholino knockdown of vars2 recapitulates cardiac and neuronal defects.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with specific VARS2 mutations. For example, a VARS2 knockout line can be generated by introducing a frameshift mutation, while a knock-in line can carry a patient-specific missense mutation (e.g., p.Arg457His). These models are sequence-verified and can be used to study mitochondrial function, screen drugs, and validate therapeutic targets. Commercially available, sequence-verified models accelerate research by providing consistent and reproducible tools.

Knockout and knock-in lines are used to validate the functional impact of VARS2 mutations. For example, a VARS2 knockout line can be complemented with wild-type or mutant VARS2 to assess rescue of mitochondrial function. This helps confirm pathogenicity of variants and elucidate genotype-phenotype correlations.

Isogenic pairs (wild-type vs. mutant) are ideal for high-throughput screening of compounds that improve mitochondrial function. For instance, screening for molecules that increase ATP production or reduce ROS can be performed. Resistance models can be developed by exposing cells to increasing concentrations of mitochondrial toxins to identify adaptive mechanisms.

CRISPR synthetic lethality screens can identify genes that, when knocked down, selectively kill VARS2-mutant cells but not wild-type cells. This can reveal potential therapeutic targets and biomarkers for patient stratification.